|
|
Volumn 49, Issue 11, 2010, Pages 2217-2219
|
|
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
a
|
|
Author keywords
Adalimumab; Adverse event; Anti TNF therapies; British society for rheumatology; Drug safety; Etanercept; Guidelines; Infliximab; Rheumatoid arthritis
|
|
Indexed keywords
ADALIMUMAB;
ANTIFUNGAL AGENT;
ANTIINFECTIVE AGENT;
ANTIRETROVIRUS AGENT;
ANTIVIRUS AGENT;
CERTOLIZUMAB PEGOL;
ETANERCEPT;
GOLIMUMAB;
HEPATITIS B VACCINE;
HERPES ZOSTER IMMUNOGLOBULIN;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
INFLUENZA VACCINE;
METHOTREXATE;
PNEUMOCOCCUS VACCINE;
TUBERCULOSTATIC AGENT;
TUMOR NECROSIS FACTOR INHIBITOR;
ARTICLE;
AUTOIMMUNE DISEASE;
CHICKENPOX;
CLINICAL PRACTICE;
CLINICAL PROTOCOL;
DEMYELINATION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG SAFETY;
DRUG WITHDRAWAL;
HEART FAILURE;
HEPATITIS B;
HEPATITIS C;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNIZATION;
IMMUNOSUPPRESSIVE TREATMENT;
INFECTION;
INFLUENZA;
LUPUS LIKE SYNDROME;
LYMPHOPROLIFERATIVE DISEASE;
MEDICAL SOCIETY;
MYCOBACTERIOSIS;
MYCOBACTERIUM TUBERCULOSIS;
OPPORTUNISTIC INFECTION;
PATIENT MONITORING;
PHYSICIAN;
PNEUMOCOCCAL INFECTION;
POSTOPERATIVE INFECTION;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PSORIASIS;
RHEUMATOID ARTHRITIS;
RISK ASSESSMENT;
RISK FACTOR;
SCREENING TEST;
SEROLOGY;
SKIN CANCER;
SOLID TUMOR;
TUBERCULOSIS;
UVEITIS;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DRUG MONITORING;
GREAT BRITAIN;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
PATIENT SELECTION;
PRACTICE GUIDELINES AS TOPIC;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 78649381672
PISSN: 14620324
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/keq249a Document Type: Article |
|
Times cited : (171)
|
|
References (4)
|
